Molecular targets in malignant pleural mesothelioma treatment

Current Drug Targets

Volumn 10, Issue 12, 2009, Pages 1235-1244

  Pasello, Giulia ^a   Favaretto, Adolfo ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Angiogenesis; Apoptosis; Growth factor; Mesothelioma; Targeted therapies

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 5,6 DIHYDROAZACITIDINE; ARENEGYR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; OCTREOTIDE; PEMETREXED; PLACEBO; PROTEASOME INHIBITOR; RANPIRNASE; RIBONUCLEASE INHIBITOR; SEMAXANIB; SOMATOMEDIN C DERIVATIVE; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; GENE LOCUS; HUMAN; LUNG CANCER; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; HEPATOCYTE GROWTH FACTOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESOTHELIOMA; PLATELET-DERIVED GROWTH FACTOR; PLEURAL NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MET; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 72849130471     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789753200     Document Type: Review

References (68)

1. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006; 42: 2706-2714 (Pubitemid 44584672)
2. Weiner SJ, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol 2009; 135(1):15-27.
3. Pisick E, Salgia R. Molecular biology pf malignant mesothelioma: a review. Oncol Clin North Am 2005; 19(6): 997-1023.
4. Steele JP, Klabatsa A, Fennell DA, Pallaska A, Sheaff MT, Evans MT et al. Prognostic factors in mesothelioma. Lung Cancer 2005; 49(1S): S49-52.
5. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007; 45(3): 379-387 (Pubitemid 47217199)
6. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapelural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
7. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004; 22(17): 3451-3457
8. Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007; 57: 89-95. (Pubitemid 46843340)
9. De Perrot M, Feld R, Cho BCJ, Bezjac A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27 (9): 1413-1418
10. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. J Clin Oncol 2009; Apr 13 [Epub ahead of print] DOI: 10.1200/JCO2008.20.3943.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644
12. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24(9): 1443-1448 (Pubitemid 46622011)
13. Zucali PA, De Vincenzo F, Simonelli M, Santoro A. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther 2009; 9(4): 453-467
14. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9(2-3): 171-179
15. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma. Cancer Res 2006; 66(1): 352-361 (Pubitemid 43166042)
16. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett 2006; 239: 183-189 (Pubitemid 43996826)
17. Dowell JE, Kindler HL. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin N Am 2005; 19: 1137-1145
18. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma [abstract]. J Clin Oncol 2007; 25(18S):7526.
19. Dowell J, Taub R, Lan C, Xie Y, Dunphy F, Blake V, et al. A multicenter phase II study of pemetrexed, cisplatin, and bevacizumab in patients with advanced malignant mesothelioma. J Clin Oncol 2009; 27(15S): 401s (Abstr. 7578).
20. Nutt JE, O'Tool K, Gonzalez D, Lunec J. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. Eur J Cancer 2009; Mar 23 [Epub ahead of print].
21. Nowak AK, Millward MJ, Francis R, van der Schaaff A, Musk AW, Byrne MJ. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2008; 26 (15S): Abstract 8063.
22. Garland LL, Chansky K, Wozniak A, Tsao A, Gadgeel S, Vershraegen C, et al. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009; 27(15S): 384s (Abstr. 7511).
23. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with Malignant pleural mesotelioma. Lung Cancer 2005; 48(2): 291-296
24. Pavlakis N, Abraham R, Harvie R, Brock C, Bell D, Boyle F, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies [abstract]. Lung Cancer 2003; 41(2S): S11.
25. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: 912.
26. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL. A phase II trial of imatinib mesylate in patients with malignant mesothelioma. Proc Am Soc Clin Oncol 2004; 22 (14s):7200.
27. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesotelioma: a phase II trial. Lung Cancer 2005; 50(1): 83-86 (Pubitemid 41297473)
28. Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007; 62(8):690-695 (Pubitemid 47235011)
29. Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008; 14(2):541-548
30. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007; 6(7): 1962-1972
31. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 2009; 10(1): 36-41.
32. Mehran R, Gil J, Rice D, Swisher S, Lee JJ, Lippman S, et al. Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. J Clin Oncol 2009; 27(15S): 402s (Abstr. 7580).
33. Cipriani NA, Abidoy OO, Vokes E, Salgia R. MET as a target for treatment of chest tumours. Lung Cancer 2009; 63(2): 169-179
34. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003; 63(17): 5462-5469
35. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005; 11:8122-8130
36. Ceresoli GL, Gregorc V, Zucali PA, Noberasco C, Bajetta E, Santoro A et al. Phase II clinical trial of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19(8S): abstract 334 p.
37. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144 (Pubitemid 41058345)
38. Destro A, Ceresoli GL, Falleni L, Zucali PA, Morenghi E, Bianchi P, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 2006; 51: 207-215
39. Edwards GJ, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression and associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006; 54: 399-407.
40. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008; 134: 1105-1111
41. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002; 62: 5242-5247 (Pubitemid 35024597)
42. Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 2300-2304
43. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25(17): 2406-2413
44. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009; Apr 20 [epub ahead of print].
45. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008; 113: 808-814
46. Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 2008; 265: 55-66.
47. Kai K, D'Costa S, Sills RC, Kim Yongbaek. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009; 278: 49-55.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
49. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164
50. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004; 5(6): 354-362
51. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109(8):1454-1461 (Pubitemid 46595678)
52. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma methylation. Lung Cancer 2002; 38:131-136 (Pubitemid 35154376)
53. Vogelzang NJ, Herndon JE 2nd, Cirrincione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997; 79(11):2237-2242
54. Samuels BL, Herndon JE 2nd, Harmon DC, Carey R, Aisner J, Corson JM, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma : a phase II study by the Cancer and Leukemia Group B. Cancer 1998; 82(8): 1578-1584
55. Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, et al. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a . J Thorac Oncol 2008; 3(4): 417-421
56. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; Apr 7 [epub ahead of print]
57. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006; 7: 257-261 (Pubitemid 43280028)
58. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009; 15(8): 2818-2828
59. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23(36): 9394-9407
60. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel R. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007; 6:66. (Pubitemid 350278695)
61. Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted terapies for malignant mesotelioma. Curr Med Chem 2008; 15(9): 855-867 (Pubitemid 351736408)
62. Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009; Apr 21 [Epub ahead of print].
63. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61(4): 549-558
64. Yuan B-Z, Chapman JA, and Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Translat Oncol 2008; 1(3): 129-140
65. Reck M, Krzakowski M, Jassem J, Eschbach C, Kozielski J, Costanzi JJ, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin versus doxorubicin in patients with unresectable malignant mesothelioma. J Clin Oncol 2009; 27 (15S): 383s (Abstr.7507).
66. Jahan TM, Gu L, Wang X, Kratzke RA, Dudek AZ, Green MR, et al. Vatalanib for patients with previously untreated advanced malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 2006; 24(18S): Abstract 7081.
67. Kindler HL, Vogelzang NG, Chien K, Stadler WM, Karczmar G, Heimann R, et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001; abstract 1359.
68. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant mesothelioma: a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 2007; 25 (17S): Abstract 7707.